article thumbnail

Why radiopharmaceuticals are gaining ground in the fight against cancer

Drug Target Review

At the forefront of this transformation is Dr Ebrahim Delpassand, a nuclear medicine physician and the driving force behind RadioMedix (RMX), a radiopharmaceutical company focused on developing targeted diagnostics and therapies. In 2006, he founded RadioMedix, a clinical stage biotechnology company, based in Houston, Texas.

Therapies 100
article thumbnail

Strategic planning in ADC development: insights from Lonza

Drug Target Review

Bioconjugates are rapidly emerging as a key frontier in targeted therapies, particularly through Antibody-Drug Conjugates (ADCs) , which combine antibodies with cytotoxic drugs to deliver more precise and effective treatments. He holds a degree in management from the University of St.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Inavolisib

New Drug Approvals

3] Primary endocrine resistance was defined as relapse while on the first two years of adjuvant endocrine therapy (ET) and secondary endocrine resistance was defined as relapse while on adjuvant ET after at least two years or relapse within twelve months of completing adjuvant ET. [3] 3 November 2006. 3 November 2006.

FDA 57
article thumbnail

Tofersen

New Drug Approvals

3 November 2006. Jump up to: a b New Drug Therapy Approvals 2023 (PDF). It is administered as an intrathecal injection. [3] 3] The most common side effects include fatigue, arthralgia (joint pain), increased cerebrospinal (brain and spinal cord) fluid white blood cells, and myalgia (muscle pain). [3] 25 April 2023. 25 April 2023.

article thumbnail

NERIGLIATIN

New Drug Approvals

While this therapy can decrease blood glucose level, it has limited efficacy and tolerability, causes weight gain and often induces hypoglycemia. (B) 2006/0058353 and PCT publication No’s. glipizide, glimepiride, glyburide) and meglitinides (e.g., B) Biguanides (e.g., For example, U.S. Patent publication No. Aggarwal, N.;

article thumbnail

Analyzing biosimilar market dynamics in different patient populations

Drug Patent Watch

Similarly, the European Medicines Agency (EMA) has been at the forefront of biosimilar regulation, with a well-established approval process in place since 2006. Oncology: Expanding Access to Life-Saving Treatments In the field of oncology, biosimilars have made significant inroads, particularly in supportive care and targeted therapies.

article thumbnail

Bridging the Gap in Patient Support: How GoodRx is Revolutionizing Access to Specialty Meds

Drug Channels

Divya discusses how integrating digital solutions from GoodRx can enhance engagement, streamline access to therapy, and improve patient outcomes. Read more 2006-2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. To learn more, download the GoodRx Yellow Paper: GoodRx Helps Enable Pharmas GTM Strategies.